that Charles Nicolette, chief executive officer of CoImmune, will present a corporate update on September 23, 2021 at 9:05AM EDT during the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. Dr. Nicolette will review progress in development of the company’s allogeneic CAR-CIK technology platform for the treatment of liquid and solid tumors and will be available to participate in one-on-one meetings with investors during the conference being held September 21-23, 2021.
The following link can be accessed on September 23, 2021 at 9:05 AM EDT to watch the presentation live:
https://wsw.com/webcast/oppenheimer16/clmm/2767483
A webcast of the presentation will also be available on the News page of the CoImmune website at https://www.coimmune.com/news/.
About CoImmune, Inc.
CoImmune is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-T therapy that promises enhanced efficacy with greatly reduced toxicity. Our autologous RNA-loaded dendritic cell technology for solid tumors uses amplified total tumor mRNA to program highly engineered dendritic cells to generate immune responses against neoantigens without the need to identify them.
###
Lori Harrelson
Chief Financial Officer
CoImmune, Inc.
lharrelson@coimmune.com
Media Contact:
Adam Daley
Berry & Company Public Relations
bberry@berrypr.com
212-253-8881